Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

On our forex charts, you can display historical data of 250 periods (250 minutes, hours or days), a valuable data you get for free here! You can use this history to make price behavior studies.

A line chart is a visualization of the closing prices of a security over time. A line chart graphically represents an asset's price over time by connecting a series of data points with a line.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast ...

Dr. Freedman has held executive roles at leading pharmaceutical companies including Genentech ... and other statements that are not historical fact. Forward-looking statements are based on ...

Geron is an undervalued company with a potential for significant revenue growth, especially via its first-in-class drug ...

June 02, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...